The modern longevity question is no longer simply, “How long can we live?”
Increasingly, the more useful question is:
“How can we identify important health risks early and support people to maintain health and function for as long as possible?”
Longevity medicine is developing rapidly. Advances in genomics, biomarkers, wearable technology and data analysis are creating new opportunities to understand individual health risks.
However, it is important to distinguish between what is already established in clinical practice and what remains an emerging area of research.
The potential future of longevity medicine may not be one universal “holy grail” test. Instead, it may be an increasingly integrated approach combining clinical assessment, established risk factors, genetics, biomarkers, lifestyle, environment and longitudinal health data.
The objective is not to predict an individual’s future with certainty.
It is to identify potentially important areas of risk and, where appropriate, support evidence based prevention.
The polygenic test: understanding the terrain
Genetics provides part of the picture.
Polygenic risk scores combine information from multiple genetic variants to estimate an individual’s inherited susceptibility to certain complex diseases. Unlike testing for a single pathogenic genetic variant, a polygenic approach considers the cumulative contribution of many genetic differences. [1,2]
Research has explored their potential application in conditions including cardiovascular disease and several other chronic diseases.
However, polygenic risk scores are not diagnostic tests and do not determine whether an individual will develop a particular condition. Their clinical usefulness can also vary according to the condition being assessed, the population in which the score was developed and validated, ancestry and how the result is incorporated into clinical decision making. [1,2]
For this reason, genetic information should be interpreted alongside conventional clinical risk factors and, where appropriate, through shared decision making.
The message should therefore not be:
“You are genetically destined to develop this disease.”
It is better expressed as:
“This may be an area where understanding your risk could help inform prevention and clinical decision making.”
Genetics may contribute to an assessment of susceptibility.
It does not determine an individual’s destiny.
One person, one priority
A comprehensive longevity assessment can generate a considerable amount of information.
The clinical challenge is deciding what actually matters.
Rather than focusing on every minor deviation from a reference range, a useful consultation can consider:
What are this individual’s most important established or potentially modifiable risk factors?
For one person, cardiovascular risk may be the priority.
For another, metabolic health.
For another, cancer prevention and appropriate screening.
For another, maintaining physical function and cognitive health.
The aim is not to create unnecessary anxiety around every possible future disease.
It is to prioritise interventions according to the individual’s circumstances, clinical risk and preferences.
This is where longevity medicine overlaps with conventional preventive medicine.
The three major areas of concern
Many discussions about healthy ageing ultimately return to three broad areas: cardiovascular disease, cancer and neurodegenerative disease.
Cardiovascular disease
Cardiovascular disease remains one of the major causes of morbidity and mortality worldwide.
Blood pressure, smoking, diabetes, lipid levels, physical activity, body composition, diet and genetic susceptibility can all contribute to cardiovascular risk.
Measures such as LDL cholesterol and, where clinically appropriate, apolipoprotein B can contribute to cardiovascular risk assessment.
Polygenic information may eventually provide additional information for selected individuals, but it should complement established clinical assessment rather than replace it. [1,2]
Cancer
Cancer risk is more complex because cancer represents many different diseases with different biological and genetic characteristics.
There is therefore no single universal “cancer risk test” that can accurately predict whether an individual will develop cancer.
Inherited genetic variants can be highly relevant for certain hereditary cancer syndromes, while age, family history, lifestyle, environmental factors and chance also contribute.
The appropriate objective is therefore risk assessment and prevention, rather than certainty of prediction.
Established screening programmes and clinically indicated investigations remain fundamental.
Emerging tests should not be regarded as substitutes for recommended screening.
Neurodegenerative disease
Neurodegenerative disease represents another rapidly developing area of research.
Blood based biomarkers associated with Alzheimer’s disease are attracting considerable interest. Phosphorylated tau, including p tau217, has shown promise as a biomarker associated with Alzheimer’s disease pathology.
However, this should not currently be presented as a generic “brain longevity test” or as a universal screening test for healthy individuals.
The appropriate use and interpretation of such biomarkers continues to develop.
The broader scientific question is nevertheless important:
Can biological changes associated with disease be identified before substantial clinical impairment develops?
If validated and appropriately implemented, earlier identification could eventually contribute to more personalised clinical assessment and research.
From disease detection to biological trajectory
Traditional medicine often asks:
“Is this patient healthy today?”
Longevity medicine increasingly asks another question:
“What is happening over time?”
A person may have normal measurements today while gradually developing changes in blood pressure, metabolic health, fitness, body composition or sleep.
Conversely, someone with an elevated inherited risk may maintain excellent health through effective management of modifiable risk factors.
This makes longitudinal information potentially valuable.
The objective is not to chase every numerical fluctuation.
It is to identify meaningful trends and determine whether interventions are appropriate.
Nutrition: the foundation remains familiar
Longevity medicine can sometimes become associated with increasingly complex interventions.
Yet many of the fundamentals remain remarkably familiar.
A healthy dietary pattern generally emphasises vegetables, fruit, legumes, whole grains, nuts and seeds, appropriate sources of protein, unsaturated fats and adequate fibre, while limiting excessive consumption of highly processed foods and excess energy intake.
A 2024 umbrella review published in the BMJ found associations between higher exposure to ultra processed foods and several adverse health outcomes, particularly cardiometabolic outcomes and mortality. Importantly, much of the underlying evidence was observational, and the certainty of evidence varied between outcomes. [3]
This distinction is important.
Association does not necessarily demonstrate causation.
Longevity nutrition should therefore be practical rather than ideological.
The most useful dietary pattern is one that is nutritionally sound, culturally appropriate and sustainable over many years.
Exercise is a long term investment
Physical activity is one of the most established interventions for maintaining health across the lifespan.
Regular physical activity is associated with benefits across cardiovascular, metabolic, musculoskeletal and psychological health.
The World Health Organization recommends that adults undertake 150 to 300 minutes of moderate intensity aerobic physical activity per week, or 75 to 150 minutes of vigorous activity, together with muscle strengthening activities on at least two days each week. [4]
For healthy ageing, however, exercise is about more than cardiovascular fitness.
Maintaining:
Aerobic capacity
Strength
Muscle mass
Balance
Mobility
and, where appropriate, power
can all contribute to maintaining physical function as we age.
The useful question is therefore not simply:
“How much exercise do I do?”
It is also:
“What physical capacity do I want to preserve as I get older?”
Sleep: an essential component of health
Sleep is sometimes treated as an optional lifestyle consideration.
It should instead be regarded as an important component of overall health.
Consistent, restorative sleep supports daytime function and wellbeing. Persistent sleep difficulties, excessive daytime sleepiness, symptoms suggestive of sleep apnoea or significant circadian disruption may warrant appropriate clinical assessment.
There is no single sleep intervention that is appropriate for everyone.
The emphasis should be on identifying individual problems and addressing them appropriately.
Stress and adaptive resilience
Not all physiological stress is necessarily harmful.
Exercise provides a useful example. Physical exertion creates a physiological challenge, followed by recovery and adaptation.
The broader concept of adaptive resilience describes the capacity to respond to challenges and recover appropriately.
A useful conceptual model is:
Challenge + recovery = adaptation
Whereas persistent stress combined with inadequate recovery may contribute to poorer wellbeing and reduced resilience.
The objective of longevity medicine should therefore not be to eliminate every stressor.
It should be to support healthy adaptation through appropriate physical activity, recovery, sleep, social connection and psychological wellbeing.
Nature and environmental exposure
Modern life can involve substantial amounts of indoor and sedentary time.
There is increasing interest in the relationship between exposure to natural environments and physical and psychological wellbeing. Systematic reviews have reported potential benefits from nature exposure and nature based interventions, although the evidence varies in quality and study design. [5,6]
A sensible approach does not require fear of the modern environment.
It can be remarkably simple:
Go outside.
Walk.
Spend time in natural environments.
Get appropriate daylight exposure.
Be physically active.
Reduce prolonged sedentary behaviour.
Pay attention to indoor environmental quality where relevant.
Microplastics are an important emerging area of environmental health research. However, evidence is not currently sufficient to claim that particular consumer avoidance strategies will prevent specific diseases.
As with many areas of longevity, proportion matters.
Reducing potentially unnecessary exposure may be reasonable, but this should not become another source of health anxiety.
The 2030 longevity horizon
The most interesting possibility is not that a single magical longevity test suddenly appears.
It is that several technologies increasingly converge.
Genomics can provide information about inherited susceptibility.
Blood biomarkers can provide information about particular biological processes.
Clinical measurements can establish conventional disease risk.
Wearable devices can provide longitudinal information about activity, sleep and other physiological measures.
Artificial intelligence may increasingly assist with integrating large quantities of health information.
The potential future model could therefore look something like:
Genetic susceptibility
↓
Clinical risk assessment
↓
Relevant biomarkers
↓
Lifestyle and environmental factors
↓
Individual priorities and preferences
↓
Personalised prevention
↓
Longitudinal follow up
↓
Reassessment
The period around 2030 should be regarded as a potential horizon for further development, not a promised breakthrough year.
Many technologies that are attracting attention today still require further validation, standardisation and evidence demonstrating that their use improves meaningful clinical outcomes.
That distinction is particularly important in private healthcare.
A test can be scientifically interesting without yet being clinically necessary.
The real longevity holy grail
Perhaps the real holy grail is therefore not one perfect blood test.
It is a responsible, evidence based, personalised feedback loop.
It asks:
What are my established health risks?
Are there additional inherited factors that are clinically relevant?
What is happening biologically now?
Which factors can I realistically modify?
What preventive interventions are appropriate for me?
And, over time, are those interventions making a meaningful difference?
This approach also recognises an important limitation.
Longevity assessment should complement rather than replace conventional medical care, clinically indicated investigations and established screening programmes.
It should not create false reassurance, unnecessary anxiety or the impression that future disease can be predicted with certainty.
The most sophisticated longevity medicine may ultimately be the least sensational.
It combines emerging science with established preventive medicine, interprets results in clinical context and helps patients make sustainable decisions.
The test provides information.
The patient provides the adaptation.
That may be the real holy grail of longevity:
Not simply detecting disease earlier, but identifying meaningful risk early enough to support informed decisions that may help preserve health and function for longer.
References
- Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nature Reviews Cardiology. 2022;19:291–301.
- Lennon NJ, et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nature Medicine. 2024;30.
- Lane MM, Gamage E, Du S, et al. Ultra processed food exposure and adverse health outcomes: umbrella review of epidemiological meta analyses. BMJ. 2024;384:e078310.
- World Health Organization. WHO Guidelines on Physical Activity and Sedentary Behaviour. 2020.
- Andersen L, Corazon SS, Stigsdotter UK. Nature exposure and its effects on immune system functioning: a systematic review. International Journal of Environmental Research and Public Health. 2021;18:1416.
- Nature based interventions for physical health conditions: a systematic review and meta analysis. Environmental Research. 2024.
